Zobrazeno 1 - 10
of 108
pro vyhledávání: '"Daryn Smith"'
Autor:
Muhammad Hamid, MD, Lance K. Heilbrun, PhD, Jordan Maier, MD, Kiran Devisetty, MD, Irene Connolly, MD, Isaac Kaufman, MD, Kimberlee Dobson, BSME, CCRP, Mackenzie K. Herroon, MA, Daryn Smith, MSc, Sandra Sampson, RN, OCN, Izabela Podgorski, PhD, Elisabeth I. Heath, MD
Publikováno v:
Advances in Radiation Oncology, Vol 6, Iss 4, Pp 100679- (2021)
Purpose: This study aimed to evaluate a combination of radiation therapy (RT), androgen deprivation therapy (ADT), and pexidartinib (colony-stimulating factor 1 receptor [CSF1R]) inhibitor in men with intermediate- and high-risk prostate cancer. CSF1
Externí odkaz:
https://doaj.org/article/c0553fe1059b424990935b580274d03e
Autor:
Sreenivasa R. Chinni, Michael L. Cher, Wael Sakr, Dongping Shi, Lance K. Heilbrun, Daryn Smith, Matthew Iyer, Katelyn Powell, Jason St. John, M. Katie Conley-LaComb, Louie Semaan, Rajareddy Singareddy
Supplementary Figure Legends - PDF file 86K, Description of supplementary figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::17524abdb51ef64efbbed8a7d67a08b4
https://doi.org/10.1158/1541-7786.22510098
https://doi.org/10.1158/1541-7786.22510098
Autor:
Sreenivasa R. Chinni, Michael L. Cher, Wael Sakr, Dongping Shi, Lance K. Heilbrun, Daryn Smith, Matthew Iyer, Katelyn Powell, Jason St. John, M. Katie Conley-LaComb, Louie Semaan, Rajareddy Singareddy
CXCR4 is a chemokine receptor that mediates invasion and metastasis. CXCR4 expression is transcriptionally regulated in cancer cells and is associated with aggressive prostate cancer phenotypes. Previously, we and others have shown that the transcrip
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6ae85565b2b3f186d4d0d26c5047937
https://doi.org/10.1158/1541-7786.c.6539505.v1
https://doi.org/10.1158/1541-7786.c.6539505.v1
Autor:
Sreenivasa R. Chinni, Michael L. Cher, Wael Sakr, Dongping Shi, Lance K. Heilbrun, Daryn Smith, Matthew Iyer, Katelyn Powell, Jason St. John, M. Katie Conley-LaComb, Louie Semaan, Rajareddy Singareddy
Supplementary Data - PDF file 589K, S1. Mutations in putative Ets/ERG binding sites in CXCR4 promoter oigos diminishes oligo binding with either VCaP cell nuclear extracts or in vitro translated ERG protein. S2. ERG ChIP seq analysis of VCaP cells. S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2391ee8a1c35999238505f98c368c1c
https://doi.org/10.1158/1541-7786.22510101
https://doi.org/10.1158/1541-7786.22510101
Autor:
Geoffrey I. Shapiro, Ralph E. Parchment, Robert J. Kinders, Katherine Ferry-Galow, Jiuping Ji, Yiping Zhang, Allison M. Marrero, Andrew Wolanski, Tracy Bell, Dongpo Cai, Adam Bowditch, Julie L. Boerner, Lawrence Rubinstein, Alice P. Chen, James M. Cleary, Sara M. Tolaney, Jie Zhang, Mary Jo Pilat, Daryn Smith, Scott A. Boerner, Edward A. Sausville, Lance K. Heilbrun, Angelika Burger, Jing Li, Patricia M. LoRusso
Supplementary Table 1 Pharmacokinetic parametersa of veliparib and its main metabolite (A- 925088) when veliparib was given orally alone on cycle 2 day -1 or in combination with irinotecan on cycle 2 day 8
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c0b2064298c57fd0391eb49d03cd7b2
https://doi.org/10.1158/1078-0432.22457396.v1
https://doi.org/10.1158/1078-0432.22457396.v1
Autor:
Geoffrey I. Shapiro, Ralph E. Parchment, Robert J. Kinders, Katherine Ferry-Galow, Jiuping Ji, Yiping Zhang, Allison M. Marrero, Andrew Wolanski, Tracy Bell, Dongpo Cai, Adam Bowditch, Julie L. Boerner, Lawrence Rubinstein, Alice P. Chen, James M. Cleary, Sara M. Tolaney, Jie Zhang, Mary Jo Pilat, Daryn Smith, Scott A. Boerner, Edward A. Sausville, Lance K. Heilbrun, Angelika Burger, Jing Li, Patricia M. LoRusso
Supplementary Figure Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b6dc68fd47e15bb70cf2c00da065fb6
https://doi.org/10.1158/1078-0432.22457402.v1
https://doi.org/10.1158/1078-0432.22457402.v1
Autor:
Geoffrey I. Shapiro, Ralph E. Parchment, Robert J. Kinders, Katherine Ferry-Galow, Jiuping Ji, Yiping Zhang, Allison M. Marrero, Andrew Wolanski, Tracy Bell, Dongpo Cai, Adam Bowditch, Julie L. Boerner, Lawrence Rubinstein, Alice P. Chen, James M. Cleary, Sara M. Tolaney, Jie Zhang, Mary Jo Pilat, Daryn Smith, Scott A. Boerner, Edward A. Sausville, Lance K. Heilbrun, Angelika Burger, Jing Li, Patricia M. LoRusso
Supplementary Figure S2. Dose-exposure relationships.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7cf999e0582e5c5e7ced20ed902272b7
https://doi.org/10.1158/1078-0432.22457411.v1
https://doi.org/10.1158/1078-0432.22457411.v1
Autor:
Geoffrey I. Shapiro, Ralph E. Parchment, Robert J. Kinders, Katherine Ferry-Galow, Jiuping Ji, Yiping Zhang, Allison M. Marrero, Andrew Wolanski, Tracy Bell, Dongpo Cai, Adam Bowditch, Julie L. Boerner, Lawrence Rubinstein, Alice P. Chen, James M. Cleary, Sara M. Tolaney, Jie Zhang, Mary Jo Pilat, Daryn Smith, Scott A. Boerner, Edward A. Sausville, Lance K. Heilbrun, Angelika Burger, Jing Li, Patricia M. LoRusso
Supplementary Methods, including numbered supplementary methods figures and figure legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15f8b12093f555d6054157fc56095eec
https://doi.org/10.1158/1078-0432.22457399
https://doi.org/10.1158/1078-0432.22457399
Autor:
Geoffrey I. Shapiro, Ralph E. Parchment, Robert J. Kinders, Katherine Ferry-Galow, Jiuping Ji, Yiping Zhang, Allison M. Marrero, Andrew Wolanski, Tracy Bell, Dongpo Cai, Adam Bowditch, Julie L. Boerner, Lawrence Rubinstein, Alice P. Chen, James M. Cleary, Sara M. Tolaney, Jie Zhang, Mary Jo Pilat, Daryn Smith, Scott A. Boerner, Edward A. Sausville, Lance K. Heilbrun, Angelika Burger, Jing Li, Patricia M. LoRusso
Supplementary Table 2 Pharmacokinetic parametersa of irinotecan and its main active metabolite SN-38 when irinotecan was administered as a 1.5-h intravenous infusion (100 mg/m2) alone on cycle 1 day 1 or in combination with veliparib on cycle 2 day 8
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0655e226af297ffb64a7958454d0e0f
https://doi.org/10.1158/1078-0432.22457393
https://doi.org/10.1158/1078-0432.22457393
Autor:
Geoffrey I. Shapiro, Ralph E. Parchment, Robert J. Kinders, Katherine Ferry-Galow, Jiuping Ji, Yiping Zhang, Allison M. Marrero, Andrew Wolanski, Tracy Bell, Dongpo Cai, Adam Bowditch, Julie L. Boerner, Lawrence Rubinstein, Alice P. Chen, James M. Cleary, Sara M. Tolaney, Jie Zhang, Mary Jo Pilat, Daryn Smith, Scott A. Boerner, Edward A. Sausville, Lance K. Heilbrun, Angelika Burger, Jing Li, Patricia M. LoRusso
Purpose: PARP is essential for recognition and repair of DNA damage. In preclinical models, PARP inhibitors modulate topoisomerase I inhibitor–mediated DNA damage. This phase I study determined the MTD, dose-limiting toxicities (DLT), pharmacokinet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3571f97af7038b93d2be21fdeace3d90
https://doi.org/10.1158/1078-0432.c.6523568.v1
https://doi.org/10.1158/1078-0432.c.6523568.v1